Skip to content Skip to navigation

ADNIV

Autosomal dominant neovascular inflammatory vitreoretinopathy (ADNIV) is an autoimmune disease of the eye without systemic features.

This eye-specific, inflammatory condition is characterized by the early presence of vitreous inflammation and loss of the ERG b-wave. The disease is progressive and complicated by pigmentary retinal degeneration, panuveitis, cystoid macular edema, retinal and iris neovascularization, epiretinal membrane formation, vitreous traction on the retina, vitreous hemorrhage, retinal detachment, and blindness.

The eye is an immune privileged site where the local immunological mechanisms are poorly understood. We believe understanding the cause of ADNIV will provide tremendous insight into more common eye diseases including uveitis, diabetic retinopathy, and proliferative vitreoretinopathy.

We are conducting studies into the genetics, proteomics and surgical therapy of this complex disease.

 

Please contact us for a consultation or to learn how you can support our research program.

Projects

We are using proteomics to study the vitreous fluid from eyes with ADNIV.

News

Jan 31 2020 | Posted In: 20/20 Blog
Palo Alto, CA —  In the article published in the January 2020 issue of Cell Reports, “Structural insight
Sep 5 2019 | Posted In: 20/20 Blog, Press
Palo Alto, CA – The Stanford Ophthalmology Department highlighted its  clinical, surgical, and research achievements in its first annual report
Jul 19 2019 | Posted In: 20/20 Blog
Pacific Grove, CA – Every three years The Biology of Calpains in Health and Disease Conference brings together an international, multidisciplinary group of researchers who are examining the role calpains play in diseases like re
Feb 25 2019 | Posted In: 20/20 Blog
Palo Alto, CA —The Mahajan Lab in Stanford University’s Department of Ophthalmology is one of four 2018 recipients of the Stanford Alliance for Innovative Medicines (AIM) Grant.
Feb 4 2019 | Posted In: 20/20 Blog
Palo Alto, CA — How can physicians and scientists make clinical trials faster, cheaper, and more likely to succeed? The answer may be proteomic analysis.
See more news

Publications

Calpains as mechanistic drivers and therapeutic targets for ocular disease., Vu, Jennifer T., Wang Elena, Wu Jolan, Sun Young Joo, Velez Gabriel, Bassuk Alexander G., Lee Soo Hyeon, and Mahajan Vinit B. , Trends Mol Med, 2022 08, Volume 28, Issue 8, p.644-661, (2022)
Genetics of Uveitis., Cunningham, Emmett T., Pichi Francesco, Mahajan Vinit B., Rosenbaum James T., and Zierhut Manfred , Ocul Immunol Inflamm, 2021 Feb 17, Volume 29, Issue 2, p.215-218, (2021)
Molecular Surgery: Proteomics of a Rare Genetic Disease Gives Insight into Common Causes of Blindness., Velez, Gabriel, and Mahajan Vinit B. , iScience, 2020 Nov 20, Volume 23, Issue 11, p.101667, (2020)
Phenotypic variance in Calpain-5 retinal degeneration., Tang, Peter H., Chemudupati Teja, Wert Katherine J., Folk James C., Mahajan Maryann, Tsang Stephen H., Bassuk Alexander G., and Mahajan Vinit B. , Am J Ophthalmol Case Rep, 2020 Jun, Volume 18, p.100627, (2020)
Proteomic analysis of intermediate uveitis suggests myeloid cell recruitment and implicates IL-23 as a therapeutic target., Sepah, Yasir J., Velez Gabriel, Tang Peter H., Yang Jing, Chemudupati Teja, Li Angela S., Nguyen Quan D., Bassuk Alexander G., and Mahajan Vinit B. , Am J Ophthalmol Case Rep, 2020 Jun, Volume 18, p.100646, (2020)
Structural Insights into the Unique Activation Mechanisms of a Non-classical Calpain and Its Disease-Causing Variants., Velez, Gabriel, Sun Young Joo, Khan Saif, Yang Jing, Herrmann Jonathan, Chemudupati Teja, MacLaren Robert E., Gakhar Lokesh, Wakatsuki Soichi, Bassuk Alexander G., et al. , Cell Rep, 2020 Jan 21, Volume 30, Issue 3, p.881-892.e5, (2020)
See more publications